London-based health-tech startup Myota has raised $4.5 million in a Series A round led by PeakBridge.
The company develops data-driven, microbiome-focused fibre mixes and a digital health platform aimed at improving well-being and preventing chronic disease. Myota said the new funding will be used to grow its direct-to-consumer platform, expand its B2B ingredients business across Europe and the US, and support further clinical research.
The company said it has completed seven clinical trials so far, with additional studies already underway as it seeks to build more evidence around its formulations.
The raise comes as interest in gut health, preventive care, and nutrition-linked digital health continues to grow, placing Myota at the intersection of wellness, clinical research, and functional ingredients.
The company develops data-driven, microbiome-focused fibre mixes and a digital health platform aimed at improving well-being and preventing chronic disease. Myota said the new funding will be used to grow its direct-to-consumer platform, expand its B2B ingredients business across Europe and the US, and support further clinical research.
The company said it has completed seven clinical trials so far, with additional studies already underway as it seeks to build more evidence around its formulations.
The raise comes as interest in gut health, preventive care, and nutrition-linked digital health continues to grow, placing Myota at the intersection of wellness, clinical research, and functional ingredients.